Tech
Cuban’s Cost Plus and Trump-Era Healthcare: Repricing the System from the Outside In
In the fragmented landscape of American healthcare, few sectors exhibit as much opacity and pricing volatility as the pharmaceutical industry. Prescription drug costs in the United States remain among the highest globally, with patients often facing unpredictable markups, limited transparency, and complex insurance negotiations. Against this backdrop, the emergence of the Mark Cuban Cost Plus Drug Company represents a notable deviation from conventional pharmaceutical business models. Founded with the explicit goal of reducing drug prices through transparent pricing and direct-to-consumer distribution, the company has gained attention not only for its celebrity affiliation but for its structural challenge to entrenched industry
Amara Okafor ·